会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Use of midkine protein and the protein-containing medical device
    • 使用中期蛋白和含蛋白质的医疗器械
    • US09283300B2
    • 2016-03-15
    • US13322443
    • 2010-05-25
    • Wei HanZhonghui Zhang
    • Wei HanZhonghui Zhang
    • A61K38/17A61P19/02A61L27/54A61L27/24A61L27/22A61K38/18A61F2/30
    • A61L27/227A61F2/30756A61F2002/30677A61K38/18A61L27/54A61L2300/252A61L2300/414A61L2430/06
    • The applications and medical devices of Midkine in the field of biotechnology are described in this invention. This invention describes the applications of the protein as follow in (a) or (b) in preparing drugs for promoting cartilage growth or treating cartilage diseases, the protein as a growth factor for promoting chondrocyte proliferation, or medical devices containing this protein: (a) the protein whose amino acid sequence is shown as SEQ ID NO.1; (b) the proteins whose amino acid sequence have at least 60% homology comparing with amino acid sequence described in (a). The present invention is different from the present knowledge of MK and its related proteins. The experimental results demonstrated that MK promotes proliferation of three types of chondrocytes and is used for preparing drugs for treating cartilage disease. It may provide new therapy for treating cartilage diseases clinically, and new technology for expansion of chondrocytes in vitro for cartilage tissue engineering.
    • 本发明描述了Midkine在生物技术领域的应用和医疗设备。 本发明描述了如下(a)或(b)中的蛋白质在制备用于促进软骨生长或治疗软骨疾病的药物中的应用,所述蛋白质作为促进软骨细胞增殖的生长因子,或含有该蛋白质的医学装置:(a )其氨基酸序列显示为SEQ ID NO.1的蛋白质; (b)与(a)中所述的氨基酸序列相比,其氨基酸序列具有至少60%同源性的蛋白质。 本发明与MK及其相关蛋白质的现有知识不同。 实验结果表明,MK促进三种软骨细胞增殖,用于制备治疗软骨疾病的药物。 可能提供临床治疗软骨疾病的新疗法,软骨组织工程体外软骨细胞扩增的新技术。
    • 10. 发明授权
    • Thiophene derivatives as factor XIa inhibitors
    • 噻吩衍生物作为因子XIa抑制剂
    • US08466295B2
    • 2013-06-18
    • US12097068
    • 2006-12-13
    • Wei Han
    • Wei Han
    • C07D231/56C07D333/22A61K31/415A61K31/38
    • C07D333/24C07D333/28C07D409/04
    • The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, L1, R3, and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    • 本发明提供式(I)的化合物或其立体异构体,互变异构体,药学上可接受的盐,溶剂合物或前药,其中变量A,L1,R3和R11如本文所定义。 式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆激肽释放酶。 特别地,它涉及作为选择性因子XIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。